drugset / Trial / NCT01558310

A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis

NCT01558310

RandomizedCrossoverTriple-blindTreatment

Summary

This is a single site, randomized, placebo-controlled, cross-over trial of sub-cutaneous injections of placebo and Stelara™ (ustekinumab) in subjects with scalp psoriasis.The purpose of the study is to assess the effectiveness of Stelara™ (ustekinumab)in the treatment of scalp psoriasis by determining the proportion of subjects who clear or almost clear in scalp specific physician assessments. The study will include approximately 30 subjects.

Timeline

Start
2012-08
Primary completion
2013-10
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ustekinumab Monoclonal antibody 45 mg Subcutaneous
Comparator Ustekinumab Monoclonal antibody 90 mg Subcutaneous

Indications